


KOPRAN LIMITED						
UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30th JUNE,2015						
(Rupees in lakhs)						
Part - I Particulars	Standalone				Consolidated	
	Quarter ended		Year ended		Quarter ended	Year ended
	30/06/2015	31/03/2015	30/06/2014	31/03/2015	30/06/2015	31/03/2015
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
Net Sales/ Income from Operations	4259	10531	6689	31,845	6,094	31,849
Other Operating Income	132	249	149	714	168	724
Total Income from operations	4391	10780	6838	32559	6262	32573
Expenditure						
Changes in Inventories of Finished Goods, Work-in- Progress and stocks- in-trade	(43)	870	(126)	337	(270)	337
Cost of Materials Consumed	1915	6322	4533	20,713	3,133	20,720
Purchase of Stock- in - trade	928	25	42	131	926	131
Employee Benefits Expenses	392	867	592	2,883	690	2,883
Depreciation	75	(11)	316	958	198	964
Other Expenses	697	1711	1080	5,333	1,271	5,336
Total Expenses	3964	9784	6437	30,355	5,948	30,371
Profit (Loss) from operations before other income, interest and exceptional items	427	996	401	2,204	314	2,202
Other Income	5	15	3	76	5	81
Foreign Exchange Gain/(Loss)	57	156	191	572	30	572
Profit (Loss) before interest and exceptional items	489	1,167	595	2,852	349	2,855
Finance Cost	233	376	292	1,297	290	1,297
Profit (Loss) before exceptional items	256	791	303	1,555	59	1,558
Exceptional items (Net)	2	(7)	-	(7)	2	(5,471)
Profit (Loss) before tax	258	784	303	1,548	61	(3,913)
Less :Tax expenses	-	-	-	-	-	-
Net Profit (Loss) for the period / year	258	784	303	1,548	61	(3,913)
Paid up equity share Capital (Face value Rs 10/-)	4,110	4,110	3,905	4,110	4,110	4,110
Reserves excluding Revaluation Reserve as per balance sheet of previous account	-	-	-	12,181	-	3,465
Earning Per Share (EPS) Before Exceptional Item						
a) Basic	0.63	1.99	0.78	3.91	0.15	3.92
b) Diluted	0.63	1.99	0.78	3.91	0.15	3.92
Earning Per Share (EPS) after Exceptional Item						
a) Basic	0.62	1.97	0.78	3.89	0.14	(9.84)
b) Diluted	0.62	1.97	0.78	3.89	0.14	(9.84)
Part II						
(A) PARTICULARS OF SHAREHOLDING						
Public shareholding						
Number of shares	23805963	23805963	23753463	23805963	23805963	23705963
Percentage of shareholding	57.92%	57.92%	60.83%	57.92%	57.92%	57.92%
Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
Number of shares	3300000	3300000	3352500	3300000	3300000	3300000
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	19.08%	19.08%	21.92%	19.08%	19.08%	19.08%
Percentage of shares (as a % of the total share capital of the company)	8.03%	8.03%	8.59%	8.03%	8.03%	8.03%
b) Non - encumbered						
Number of shares	13993513	13993513	11943513	13993513	13993513	13993513
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter Group)	80.92%	80.92%	78.08%	80.92%	80.92%	80.92%
Percentage of shares (as a % of the total share capital of the company)	34.05%	34.05%	30.58%	34.05%	34.05%	34.05%
(B) INVESTOR COMPLAINTS						
	3 Months ended 30-06-2015					
Pending at the beginning of the quarter	-					
Received during the quarter	4					
Disposed off during the quarter	4					
Remaining unresolved at the end of the quarter	-					

Notes:-

- (1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 12th August, 2015. These results have been reviewed by the Statutory Auditor's of the company.
- (2) During the previous year the Active Pharmaceutical Ingredients business with its manufacturing facility at Mahad was transferred to Kopran Research Laboratories Ltd. a 100% subsidiary company for a consideration of Rs. 110 crores as on 31st March 2015.
- (3) The Consumer Care Division was sold on a slump sale basis for a consideration of Rs. 200 lakhs with effect from 1st April 2015, carrying an amount of net assets of Rs. 197.93 Lakhs to Kopran Lifestyle Ltd. as on 1st April 2015.
- (4) In the view of the point no 2 and 3 the quarterly figures are not strictly comparable with the immediate previous quarter and the corresponding quarter of the previous year.
- (5) The Company is now engaged primarily in the Pharmaceutical business and there are no separate reportable segments as per AS 17.
- (6) The Company has made an investment of Rs. 4490.61 Lacs and has also advanced a sum of Rs.81.27 Lakhs to Kopran Research Laboratories Ltd (KRLL), a wholly owned subsidiary of the Company, the accumulated losses of KRLL as on 30th June, 2015 are Rs.5487.89 Lakhs. The investments are of strategic and Long Term. In the opinion of the Management there is no permanent impairment in the value of investments.
- (7) The figures of the quarter ended 31st March, 2015 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to nine months of the relevant financial year.
- (8) The company has opted for consolidated financial results from Quarter ended 30th June, 2015 and hence consolidated results for corresponding quarter and previous quarters have not been given.
- (9) Figures for the previous accounting period have been regrouped wherever necessary.

KOPRAN LIMITED


Surendra Somani
Executive Vice Chairman

Place : Mumbai
Date : 12-08-2015

BATLIBOI & PUROHIT

Chartered Accountants


INDEPENDENT AUDITORS' REVIEW REPORT

TO THE BOARD OF DIRECTORS OF KOPRAN LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Kopran Limited** ("the Company") and its subsidiaries (together referred to as "the Group") for the quarter ended June 30, 2015 ('the Statement'), being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not review revenues and loss after tax of Rs. 2,803.54 lakhs and Rs. (271.85) lakhs respectively, included in the accompanying unaudited consolidated financial results relating to one subsidiary, whose financial information has been reviewed by the other auditors and whose report has been furnished to us. Our conclusion on the unaudited quarterly financial results, in so far as it relates to such subsidiary is based solely on the report of the other auditors.
4. We did not review revenues and loss after tax of Rs. Nil and Rs. (1.54) lakhs respectively, included in the accompanying unaudited consolidated financial results relating to two subsidiaries, whose financial information has not been reviewed by other auditors and is certified by the Management.
5. Based on our review conducted as stated above and based on consideration of report of other auditors on the unaudited separate quarterly financial results referred to in paragraph 3 above, and based on the other financial information of the components certified by Management referred to in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with Accounting Standards specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BATLIBOI & PUROHIT
Chartered Accountants

Firm Reg No. 101048W



KAUSHAL MEHTA

Partner

Membership No. 111749

Place : Mumbai
Dated : August 12, 2015

BATLIBOI & PUROHIT

Chartered Accountants

INDEPENDENT AUDITORS' REVIEW REPORT


TO THE BOARD OF DIRECTORS OF KOPRAN LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of **Kopran Limited ("the Company")** for the quarter ended June 30, 2015 ('the Statement'), being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the Management and have not been reviewed by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with Accounting Standards specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Without qualifying our conclusion, we draw attention to note 6 of the Statement whereby the management is of the opinion that no provision is required in respect of investment made in the subsidiary company Kopran Research Laboratories Limited for reasons stated there in.

Place : Mumbai
Dated : August 12, 2015

For BATLIBOI & PUROHIT
Chartered Accountants

Firm Reg No. 101048W



KAUSHAL MEHTA

Partner

Membership No. 111749